Funded in part by Pharmavite, Genentech
Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival
Yuan C, Qian ZR, Babic A, Morales-Oyarvide V, Rubinson DA, Kraft P, Ng K, Bao Y, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Buring JE, Cochrane BB, Chlebowski RT, Snetselaar LG, Manson JE, Fuchs CS, Wolpin BM
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 41 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cohort study (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Industry funded
- Government
- U.S. Department of Defense
- Government
- Women's Health Initiative
- Company
- Pharmavite
- Government
- National Institutes of Health
- Company
- Genentech
- Government
- National Heart, Lung, and Blood Institute
- Government
- National Cancer Institute
- Government
- NCI NIH HHS
- Government
- NHLBI NIH HHS
- Government
- WHI NIH HHS
- Grants
- National Institutes of Health (CA 34944); National Cancer Institute (CA-167552); National Cancer Institute (R01 CA138962); National Cancer Institute (K07CA148894); National Heart, Lung, and Blood Institute (R01 HL102122); National Cancer Institute (CA-49449); National Cancer Institute (CA130288); National Heart, Lung, and Blood Institute (R01 HL034595); National Cancer Institute (P01 CA087969); National Cancer Institute (UM1 CA186107); National Cancer Institute (R01CA124908); National Cancer Institute (CA-87969); National Cancer Institute (CA197735); National Cancer Institute (UM1-CA-167552); National Cancer Institute (R35CA197735); National Cancer Institute (R01-CA49449); U.S. Department of Defense (CA130288); National Cancer Institute (CA127003); National Institutes of Health (CA130288); National Cancer Institute (CA-186107); National Cancer Institute (R01 CA034944); National Heart, Lung, and Blood Institute (R01 HL026490); National Cancer Institute (R01‐CA049449); National Cancer Institute (P50-CA127003); Women's Health Initiative (24152); National Institutes of Health (N01-WH-2-2110); National Cancer Institute (UM1 CA182913); National Cancer Institute (R01 CA040360); Women's Health Initiative (N01WH22110); National Institutes of Health (24152); National Cancer Institute ([P01 CA87969); National Institutes of Health (R01 CA49449); National Institutes of Health (P01 CA 87969); National Institutes of Health (UM1 CA167552); National Institutes of Health (N01 WH022110); National Institutes of Health (P50-CA127003); National Institutes of Health (UM1‐CA‐186107); National Institutes of Health (CA 40360); National Institutes of Health (CA-167552); National Institutes of Health (HL 34595); National Institutes of Health (CA186107); National Institutes of Health (UM1 CA186107, P01 CA87969, and R01 CA49449); National Institutes of Health (CA 87969); National Institutes of Health (CA197735); National Institutes of Health (HL-26490)
Based on 10 listed funder(s).
Publication
- Published
- 2016-06-21 · J Clin Oncol · vol. 34 · issue 24 · pp. 2899–2905
- Publisher
- Lippincott Williams & Wilkins
- Cited
- 51 citations · more than 95% of similar papers · 4.6× the field average
- Impact
- Top 10% most cited in its field
- References
- 45 works
- Access
- Open access (repository copy)
- Research areas
- Vitamin D Research Studies · Pancreatic and Hepatic Oncology Research · Medical Imaging Techniques and Applications
- Keywords
- Medicine, Internal medicine, Vitamin D and neurology, Gastroenterology, Proportional hazards model, Hazard ratio, Pancreatic cancer, Prospective cohort study, Body mass index, Cancer, Cohort, Diabetes mellitus, Cohort study, Confidence interval, Endocrinology
- MeSH
- humans, carcinoma, pancreatic ductal, pancreatic neoplasms, vitamin d, prognosis, proportional hazards models, cohort studies, prospective studies, aged, united states, female, male, biomarkers, tumor
20 authors
- Chen Yuan
- Zhi Rong Qian
- Ana Babić
- Vicente Morales‐Oyarvide
- Douglas Adam Rubinson
- Peter Kraft
Abstract
Purpose
Although vitamin D inhibits pancreatic cancer proliferation in laboratory models, the association of plasma 25-hydroxyvitamin D [25(OH)D] with patient survival is largely unexplored.
Patients and methods
We analyzed survival among 493 patients from five prospective US cohorts who were diagnosed with pancreatic cancer from 1984 to 2008. We estimated hazard ratios (HRs) for death by plasma level of 25(OH)D (insufficient, < 20 ng/mL; relative insufficiency, 20 to < 30 ng/mL; sufficient ≥ 30 ng/mL) by using Cox proportional hazards regression models adjusted for age, cohort, race and ethnicity, smoking, diagnosis year, stage, and blood collection month. We also evaluated 30 tagging single-nucleotide polymorphisms in the vitamin D receptor gene, requiring P < .002 (0.05 divided by 30 genotyped variants) for statistical significance.
Results
Mean prediagnostic plasma level of 25(OH)D was 24.6 ng/mL, and 165 patients (33%) were vitamin D insufficient. Compared with patients with insufficient levels, multivariable-adjusted HRs for death were 0.79 (95% CI, 0.48 to 1.29) for patients with relative insufficiency and 0.66 (95% CI, 0.49 to 0.90) for patients with sufficient levels (P trend = .01). These results were unchanged after further adjustment for body mass index and history of diabetes (P trend = .02). The association was strongest among patients with blood collected within 5 years of diagnosis, with an HR of 0.58 (95% CI, 0.35 to 0.98) comparing patients with sufficient to patients with insufficient 25(OH)D levels. No single-nucleotide polymorphism at the vitamin D receptor gene met our corrected significance threshold of P < .002; rs7299460 was most strongly associated with survival (HR per minor allele, 0.80; 95% CI, 0.68 to 0.95; P = .01).
Conclusion
We observed longer overall survival in patients with pancreatic cancer who had sufficient prediagnostic plasma levels of 25(OH)D.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.